Long-term persistence of RBD-positive memory B cells encoding neutralising antibodies in SARS-CoV-2 infection
| Autor: | Nicky Gilroy, Nicholas A. Brasher, Hui Li, Fabienne Brilot, Romain Rouet, Stuart Turville, Alberto Ospina Stella, Mohamed A. Hammoud, Arunasingam Abayasingam, Andrew R. Lloyd, Deepti Pilli, Chaturaka Rodrigo, Rowena A. Bull, Dominic E. Dwyer, Michael J. Mina, Bernard J Hudson, Sarah Christina Sasson, Nicodemus Tedla, Fiona Tea, Daniel Christ, Deborah Burnet, Anthony D. Kelleher, Harikrishnan Balachandran, Elizabeth Keoshkerian, William D. Rawlinson, Anupriya Aggarwal, Christina Fichter, Marianne Martinello, Jeffrey J. Post, Branka Grubor-Bauk, David Agapiou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Protective immunity 2019-20 coronavirus outbreak Medicine (General) Time Factors medicine.drug_class Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) longitudinal tracking Monoclonal antibody Severity of Illness Index General Biochemistry Genetics and Molecular Biology RBD Young Adult R5-920 Protein Domains Limit of Detection Neutralization Tests Report memory B cells Medicine Humans neutralizing antibodies Memory B cell neutralising antibodies Aged Aged 80 and over biology business.industry SARS-CoV-2 COVID-19 Middle Aged Long term persistence Antibodies Neutralizing functional MBCs Antibody response Immunology Asymptomatic Diseases Spike Glycoprotein Coronavirus biology.protein Female Antibody business |
| Zdroj: | Cell Reports Medicine Cell Reports Medicine, Vol 2, Iss 4, Pp 100228-(2021) |
| ISSN: | 2666-3791 |
| Popis: | Considerable concerns relating to the duration of protective immunity against SARS-CoV-2 exist, with evidence of antibody titres declining rapidly after infection and reports of reinfection. Here we monitor the antibody responses against SARS-CoV-2 receptor binding domain (RBD) for up to six months after infection. While antibody titres are maintained, about 13% of the cohort’s neutralising responses return to background. However, encouragingly in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralising capacity from these memory B cells. Overall our study suggests that the loss of neutralising antibodies in plasma may be countered by the maintenance of neutralising capacity in the memory B cell repertoire. Graphical Abstract Abayasingam et al. report that despite the declining anti-RBD antibody titres and neutralising capacity of antibodies in the serum at six months, the memory B cells still contain RBD-specific reactivity that have the capacity to generate antibodies that can neutralise SARS-CoV-2 in vitro. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|